S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:BLUE

bluebird bio Stock Forecast, Price & News

$10.50
-0.26 (-2.42%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$10.35
$10.89
50-Day Range
$10.50
$25.19
52-Week Range
$10.21
$53.68
Volume
2.19 million shs
Average Volume
1.64 million shs
Market Capitalization
$736.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.58
30 days | 90 days | 365 days | Advanced Chart
Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.


bluebird bio logo

About bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Headlines

bluebird bio (NASDAQ:BLUE) Reaches New 1-Year Low at $10.23
November 23, 2021 |  americanbankingnews.com
bluebird bio (NASDAQ:BLUE) Shares Gap Up to $10.70
November 22, 2021 |  americanbankingnews.com
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
November 22, 2021 |  markets.businessinsider.com
bluebird bio (NASDAQ:BLUE) Receives "Hold" Rating from Berenberg Bank
November 12, 2021 |  americanbankingnews.com
bluebird bio (NASDAQ:BLUE) PT Lowered to $15.00
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
1,213
Year Founded
N/A

Sales & Book Value

Annual Sales
$250.73 million
Book Value
$12.42 per share

Profitability

Net Income
$-618.70 million
Net Margins
-1,610.78%
Pretax Margin
-1,609.99%

Debt

Price-To-Earnings

Miscellaneous

Free Float
68,074,000
Market Cap
$736.12 million
Optionable
Optionable

Company Calendar

Last Earnings
11/05/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

206th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

35th out of 201 stocks

Analyst Opinion: 4.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 15 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio
or view top-rated stocks.

How has bluebird bio's stock price been impacted by COVID-19?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BLUE stock has decreased by 82.9% and is now trading at $10.50.
View which stocks have been most impacted by COVID-19
.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to the consensus estimate of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 1,610.78%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.94) EPS.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

19 Wall Street analysts have issued 1-year price objectives for bluebird bio's shares. Their forecasts range from $10.00 to $39.00. On average, they anticipate bluebird bio's share price to reach $18.07 in the next year. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for bluebird bio
or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Nick Leschly, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jason F. Cole, Secretary, Chief Operating & Legal Officer
  • Chip Baird, Chief Financial & Accounting Officer
  • Philip D. Gregory, Chief Scientific Officer
  • Anne-Virginie Eggimann, Vice President-Regulatory Science

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.87%), BlackRock Inc. (8.54%), Credit Suisse AG (2.97%), Goldman Sachs Group Inc. (2.22%), Geode Capital Management LLC (1.73%) and EcoR1 Capital LLC (1.14%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which institutional investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Royal Bank of Canada, Morgan Stanley, Goldman Sachs Group Inc., KBC Group NV, Millennium Management LLC, BlackRock Inc., and Caption Management LLC. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, Andrew Obenshain, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio
or view top insider-selling stocks.

Which institutional investors are buying bluebird bio stock?

BLUE stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Assenagon Asset Management S.A., UBS Group AG, Voloridge Investment Management LLC, Rafferty Asset Management LLC, Dimensional Fund Advisors LP, Jane Street Group LLC, and Deutsche Bank AG.
View insider buying and selling activity for bluebird bio
or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $10.50.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $736.12 million and generates $250.73 million in revenue each year. The biotechnology company earns $-618.70 million in net income (profit) each year or ($12.82) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 1,213 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (339) 499-9300 or via email at [email protected].


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.